Our expression technologies and expertise help address challenges with new, more complex molecular formats
Antibodies still predominate in the clinic, however there is a large shift in drug development pipelines to more complex, next generation biologics, which often do not express well in current expression platforms.
We have decades of experience in developing and manufacturing novel molecular formats and other recombinant proteins, comprising approximately 40% of the large molecules our teams supported in 2021. This is achieved by leveraging extensive expertise and a breadth of innovative technologies, together with our proprietary GS Gene Expression System®.
To help you accelerate your path to the clinic, we offer integrated drug substance and drug product programs with the following typical timelines:
- Fabs & fusion proteins: from DNA to IND in 14 to 16 months*
- For scaffolds and other recombinants proteins: from DNA to IND in 15 to 18 months*
The technical scope and timelines for all programs can be tailored to your specific needs.
*Typical timelines. From DNA transfection. Subject to molecule evaluation.